ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Effectiveness and safety of intravenous iron in ulcerative colitis: A real-world study of impact of disease activity and iron preparations.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is lack of evidence on how disease activity in inflammatory bowel disease influences response to intravenous iron.
methodsA single-centre prospective study was conducted to study responses to intravenous iron in ulcerative colitis. Patients with iron deficiency anemia (hemoglobin < 8 g/dL OR < 12 g/dL with intolerance to oral iron or active disease) received protocolized intravenous iron dosing per European Crohn's and Colitis Organisation (ECCO) guidelines. Ferric carboxymaltose (FCM) or iron isomaltoside was used per patient preference. The outcomes were increase in Hb ≥ 2 g/dL, normalization of Hb at four weeks and normalization of iron indices (serum ferritin >100 ng/mL in active and > 30 ng/mL in inactive disease and transferrin saturation > 20%) assessed at four weeks.
resultsThirty-two patients (females = 21 [65.6%], mean age = 32.78 ± 12.65 years, active disease = 17 [53.1%]) received IV iron. Twenty-one received FCM, while 11 received iron isomaltoside. Complete normalization of Hb was seen in seven (41%) in active patients and nine (60%) in remission groups (p = 0.47). Normalization of iron profile was seen in 11 (64%) and 12 (80%) patients in two groups, respectively (p = 0.32). Secondary objectives of mean change in Hb and iron indices tended towards better response in inactive group, but were not statistically significant except change in transferrin saturation that was better in inactive group (20.8 ± 9.1% and 14.2 ± 8.1%, p = 0.04). FCM was associated with hypophosphatemia in 6/21 (28.5%) patients vs. none in isomaltoside group. The predictive performance for complete hematological response with the reticulocyte hemoglobin and percentage of hypochromic cells was low (area under the receiver operating characteristic [AUROC] of 0.67 and 0.685, respectively).
conclusionAlthough there was a tendency towards better response to intravenous iron in those with remission, the findings were not statistically different. Larger studies are needed to provide conclusive evidence. Iron isomaltoside may be preferable over FCM due to risk of hypophosphatemia with the latter.
Indexed as
Identifiers
40512340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.